PDB27 COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR TYPE 2 DIABETES PATIENTS IN CHINA
Nov 1, 2007, 00:00 AM
10.1016/S1098-3015(10)64975-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)64975-3/fulltext
Section Title :
Section Order :
134
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64975-3&doi=10.1016/S1098-3015(10)64975-3